Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

NCT07677891 · Not yet recruiting

Last updated 2026-07-12

This clinical trial tests whether adults with type 2 diabetes who switch from dulaglutide to PG-102(MG12) experience changes in their HbA1c levels over 32 weeks.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 19–75 · all sexes

Timeline Started 2026-10 · est. completion 2027-06

What this study is testing ClinicalTrials.gov NCT07677891 ↗

Description as written by the study sponsor.

This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy. The treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.

Treatments tested

PG-102(MG12) Drug

GLP-1 and GLP-2 fusion protein
Dulaglutide Drug

GLP-1 receptor agonist

Main thing measured	Change in HbA1c from Baseline at Week 32
Sponsor	ProGen. Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07677891 ↗